HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>We saw the collapse of Akeso's share price after the Company released the clinical data of AK112 on ASCO. Judging from the market reaction, there are indeed“something unsatisfactory” about AK112.</li>
<li>Akeso’s high valuation mainly comes from the expectation that it would be a player that can compete on international stage. But investors' confidence in AK112’s future commercialization has been shaken.</li>
<li>We advise investors to remain patient and "let the bullets fly". It's not yet time for the final result.But, if you want to bet, you need to pay the price.</li>
</ul>


We saw the collapse of Akeso's share price after the Company released the clinical data of AK112 on ASCO. Judging from the market reaction, there are indeed“something unsatisfactory” about AK112.
Akeso’s high valuation mainly comes from the expectation that it would be a player that can compete on international stage. But investors' confidence in AK112’s future commercialization has been shaken.
We advise investors to remain patient and "let the bullets fly". It's not yet time for the final result.But, if you want to bet, you need to pay the price.


Akeso Biopharma (9926.HK) - It's Not Game over Yet

United States

Summit Therapeutics Inc. operates as a biopharmaceutical company. The Company focuses on developing new mechanism antibiotics for the treatment of people with infectious diseases. Summit Therapeutics serves customers in the United States and the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Summit Therapeutics (SMMT US)

Akeso Biopharma (9926.HK) - It's Not Game over Yet

Akeso's share price plunged after unsatisfactory clinical data release for AK112 at ASCO, raising doubts about international...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Akeso Biopharma (9926.HK) - It's Not Game over Yet

​Akeso's share price plunged after unsatisfactory clinical data release for AK112 at ASCO, raising doubts about international...

Xinyao (Criss) Wang

Akeso's share price plunged after unsatisfactory clinical data release for AK112 at ASCO, raising doubts about international...